Clinical Trial: A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852222) titled 'A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)' on Feb. 25.

Brief Summary: The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML).

Study Start Date: May 02

Study Type: INTERVENTIONAL

Condition: Leukemia, Myeloid, Acute

Intervention: DRUG: Bleximenib

Bleximenib will be administered orally.

DRUG: Venetoclax (VEN)

VEN will be administered orally.

DRUG: Azacitidine (AZA)

AZA will be administered intravenously...